|Publication number||US3592930 A|
|Publication date||Jul 13, 1971|
|Filing date||Jul 19, 1968|
|Priority date||Jul 19, 1968|
|Also published as||CA989304A, CA989304A1, DE1934334A1, DE1934334B2, DE1934334C3|
|Publication number||US 3592930 A, US 3592930A, US-A-3592930, US3592930 A, US3592930A|
|Inventors||Katz Martin, Neiman Herbert M|
|Original Assignee||Syntex Corp|
|Export Citation||BiBTeX, EndNote, RefMan|
|Referenced by (49), Classifications (7), Legal Events (6)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent MOlSTURE-DETERIORATABLE TOPICAL MEDIC- AMENTS, PARTICULARLY ANTI-INFLAMMA- TORY STEROIDS, IN A SUBSTAN'HALLY NON- AQUEOUS FATTY ALCOHOL-PROPYLENE GLY- COL VEHICLE Martin Katz, Atherton, Calif, and Herbert M. Neiman, Philadelphia, Pa., assignors to Syntex Corporation, Panama, Panama No Drawing. Filed July 19, 1968, Ser. No. 745,989
Int. Cl. Aolk 9/10, 17/06, 27/10 US. Cl. 424-443 10 Claims ABSTRACT OF THE DISCLOSURE A substantially non-aqueous medicant vehicle containing from to 45 parts saturated fatty alcohol having from 16 to 24 carbons, from 55 to 85 parts glycol solvent, from 0 to 10 parts plasticizer, from O to 10 parts coupling agent, 0 to parts penetrant, and if desired, other pharmaceutical adjuvants. This base is a suitable vehicle for all types of therapeutic agents for topical application including antibiotics, steroids, antihistamines, antiseptics, anesthetics, antibacterials, fungicides, and the like. The vehicle has shown particular advantages with anti-inflammatory topical corticoids.
This invention relates to vehicles for topical applications of medicants (i.e., active ingredients) and to mixtures of the vehicles and medicants. In particular, this invention relates to new, improved medicant vehicles having advantages over previously known vehicles.
One of the oldest types of medicant vehicles is the ointment, a preparation containing active medications that can be readily spread on and rubbed into the skin. It serves as a means for distributing the medication uniformly over the skin surface and maintaining it there until beneficial action can occur. The earlier preparations were based on fats, greases and petrolatum. These are, by nature, greasy, are not water-washable and have a limited ability to release medication to the skin. A nonaqueous ointment of more recent origin is Carbowax, a grease-like mixture of polyethylene glycols (molecular weight of 1000 to 20,000). This vehicle, although waterwashable, has a greasy texture and does not provide an occlusive coating on a treated surface. Prior to this invention, these anhydrous ointment bases were the only vehicles available for medicants which deteriorate in the presence of moisture.
Emulsified creams, such as cold creams, were developed to reduce greasiness, while still maintaining the unctuousness and spreadability of the older grease-type ointments. The emulsified creams have an aqueous base, however, and are not suitable as vehicles for many drugs because their pH or water content may destroy the medicant. The medicant, in turn may destroy the emulsions, that is, break the emulsions and permit separation of the vehicle components. These emulsions also must contain surfactants as emulsifiers and wetting agents.
It is accordingly the purpose of this invention to provide an essentially anhydrous, water-washable base which is more effective than standard anhydrous ointment bases of the grease-type because it can preserve the activity of medicants which deteriorate in the presence of moisture; provide an occlusive film for longer and better therapeutic activity; release the medicants more quickly and effectively; bring dissolved anti-bacterial agents in known dilution in contact with the skin; spread evenly and adhere well even if the skin is moist; be easily removed with water from skin or fabrics; be soluble in water and thus 3,592,930 Patented July 13, 1971 TABLE A Concentration 1 Ingredient Operable Preferred Fatty alcohol 15-45 20-35 Glycol solvent 45-85 65-80 Compatible plasticizer. 0-15 2-10 Compatible coupling agent 0-15 l-5 Penetrant 0-20 0-10 1 Weight percent or parts by weight per parts.
All concentrations are herein given as weight percents or parts by weight unless otherwise specified. It is also intended that the chemical compounds in each class of ingredients discussed hereinafter be limited to pharmaceutically acceptable compounds in the concentrations indicated.
The fatty alcohol ingredient in the vehicle composition of this invention can be any saturated fatty alcohol having from 16 to 24 carbons or mixtures thereof, and is preferably a monohydric primary alcohol. Suitable fatty alcohols include cetyl alcohol, stearyl alcohol, behenyl alcohol, and the like. Vehicles having excellent properties have been made using stearyl alcohol, or mixtures of cetyl, stearyl and behenyl alcohols as the fatty alcohol component. The fatty alcohol component must be substantially free from any significant amount of unsaturated alcohols or fatty alcohols having fewer than 16 carbons. The terms substantially free from, as used herein, is defined as indicating the compositions of this invention contain less than irritating or otherwise medically undesirable amounts of the indicated substances. Since the C to C fatty alcohols available commercially contain impurities including some proportion of fatty alcohols having fewer than 16 carbons, total avoidance of alcohols having fewer than 16 carbons from the mixture is not practicable. Careful selection of raw materials is preferable, however, to maintain the percentage of irritating fatty alcohols to less than 10 percent of the total fatty alcohol concentration.
The glycol solvent component can be a propylene glycol such as 1,2-propylenediol, 1,3-propylenediol, polyethylene glycol having a molecular weight of from 100 to 800, dipropylene glycol, etc., and mixtures thereof.
The fatty alcohol and glycol solvent ingredients are the principle components and are satisfactory as the sole vehicle components in the composition of this invention. The glycol solvent can function either as a solvent for a glycol-soluble medicant or a carrier for a glycol-insoluble medicant. The fluidity of the composition increases with increased concentrations of the glycol solvent. In the combination with the glycol solvent, the fatty alcohol (a solid component which naturally thickens the composition) forms a unique protective, lubricant and occlusive film which is highly desirable in several types of dermatological preparations.
The composition can also contain a compatible plasticizer such as polyethylene glycol having a molecular weight of from above 800 to 20,000, 1,2,6-hexanetriol, sorbitol, glycerol, and the like. The plasticizer maintains homogeneity in the fatty alcohol-glycol solvent mixture at ambient temperatures that is, temperatures at which the fatty alcohol is naturally a solid. This component also improves the plasticity and uniformity of medicant mixtures with the vehicle and provides to the vehicle smoothness and a more pleasing feel; hence the vehicle containing the plasticizer is more pharmacologically acceptable.
The term compatible is defined herein to indicate a component which will not cause separation (loss of homogeneity) of the other components, that is, the fatty alcohol and glycol solvent at temperature up to 45 C.
The plasticizer concentration can be within the range of from to percent. Concentrations above 15 percent may provide a composition which has a consistency unsuitable for normal applications or cause instability of the vehicle mixture and some separation of the components. In general, the particular plasticizer concentration necessary to provide a desired consistency, degree of smoothness and plasticity will vary with the choice of the fatty alcohol component, the choice of glycol solvent, and the ratio of these components in the vehicle.
The particular concentration of plasticizer which will provide the most stable composition will depend upon the choice of plasticizer, and choice and concentration of the other ingredients. Preferably, the plasticizer concentration should be balanced so the vehicle has freeze-thaw stability, i.e., does not separate after repeated cycles of solidification (by cooling) and liquefaction (by heating).
The vehicle of this invention can also contain a compatible, pharmaceutically acceptable coupling agent, the term compatible having the above-defined meaning. Suitable coupling agents include saturated fatty acids having from 16 to 24 carbons such as stearic acid, almitic acid, behenic acid; fatty amides such as oleamide, palmitamide, stearamide, behenamide; and esters of fatty acids having from 16 to 24 carbons such as sorbitan monostearate, polyethylene glycol monostearate, propylene glycol monostearate and the corresponding mono-esters of other fatty acids such as oleic acid and palmitic acid. Best coupling is achieved, particularly with the esters, if the fatty group of the coupling agent and fatty alcohol is the same or has approximately the same number of carbons. It is essential that the fatty acids be saturated and the fatty acids and amides be essentially free from irritating amounts of acids or amides having fewer than 16 carbons.
The coupling agent concentration can be within the range of from O to 10 percent. In general, the coupling agents maintain homogeneity of the vehicle and prevent exudation or bleeding of the more liquid components of the vehicle (glycol solvent) upon prolonged storage at elevated temperatures. The medicant vehicle preferably contains a quantity of the coupling agent sufficient to prevent visible exudation of the glycol solvent from the vehicle after storage at for 48 hours. No more of the coupling agent is required than is needed to prevent this exudation. Excess quantities are undesirable because other ingredients and their functions are needlessly diluted. If the coupling agent concentration is not carefuly balanced with the other components, stability of the medicant vehicle after one or more repeated cycles of solidification (by cooling) and liquefaction (by heating), that is, the freeze-thaw stability is impaired.
The penetrants increase the penetration and therapeutic activity of the medicants and are usually solvents or cosolvents for the medicants. The penetrants can be used in concentrations which are pharmaceutically acceptable for the intended use not to exceed 20 percent of the weight of the vehicle. Representative examples of penetrants include dimethylsulfoxide, dimethylacetanide, dimethylformamide, and the like.
It should be understood that the medicant vehicles of this invention can also contain non-essentiall ingredients. The vehicle can contain up to 10 Weight percent of conventional pharmaceutical adjuvants. These adjuvants or additives are conventionally used to improve consistency, homogeneity, spreadability, texture and appearance of the vehicle or its residual film. They can be used to give to a residual film, varying degrees of continuity, flexibility, ad-
hesion, occlusion, water repellancy, washability, and the like. Examples of typical adjuvants include surfactants (cationic, anionic, or nonionic) such as Pluronics, polyoxyethylene-polyoxypropylene copolymers; gums such as natural gums including agar, acacia gum, guar gum, tragacanth, and the like; cellulose derivatives including cellulose ethers such as methyl cellulose, ethyl cellulose, carboxymethyl cellulose, and the like; starch and starch derivatives; and water-soluble vinyl polymers such as polyvinylpyrrolidone, polyvinyl acohol, vinylpyrrolidone-vinyl alcohol copolymers, and the like.
The vehice base of this invention does not contain any significant quantity of petrolatum or mineral oil. It is therefore not a classical ointment and is not Waterinsoluble.
The medicant vehicle of this invention is essentially a non-aqueous base, that is, it is not an emulsion and consequently is not a cream in the technical sense. It is preferably anhydrous, but can contain minor amounts of water such as up to 3 percent water. The water concentration should not be sufiicient to cause separation of the other vehicle components or precipitant medicants dissolved in the vehicle.
The vehicle of this invention can be made from the above ingredients by thoroughly mixing them at ambient or elevated temperatures. Preferably the components are thoroughly mixed while each is in a liquid state, and the mixture is cooled with good agitation to room temperature. By way of referring to a preferred composition as an example, cetyl alocohl, stearyl alcohol, bethenyl alcohol, stearic acid, polyethylene glycol and 1,2,6-hexanetriol can be mixed with stirring to about -85" C.; propylene glycol can be heated to 95 C. with stirring (a medicant stable at this temperature could be added to either phase during this step); and the two liquids can be mixed with stirring. Good agitation is provided until the mixture cools to room temperature.
If desired, additional mechanical agitation and/or shock cooling steps can be used as intermediate or final steps in the manufacturing process to impart more homogeneity or improve texture. Processing equipment suitable for these steps is known and includes heat exchangers, propeller mixers, colloid mills, homogenizers, roller mills, and the like.
The base of this invention can be used successfully as a vehicle for most types of therapeutic agents for topical application including antibiotics such as oxytetracycline, chlortetracycline, streptomycin, bacitracin, chloramphenical, tyrothricin and the like; steroids having anti-inflammatory or other beneficial activity; antihistamines such as prophenpyridamine maleate and diphenhydramine hydrochloride; anesthetics such as benzocaine and lidocaine; antibacterials including iodine, nitrofurazone, sulfanilamide and derivatives, and benzalkonium chloride; fungicides such as undecylenic acid; and older therapeutic agents including coal tar, balsam Peru, ammoniated mercury, chrysarobin, ichthammol, sulfur, and the like.
In corporation of the medicament in this base requires no deviation from standard techniques such as those described in Remingtons Practice of Pharmacy, 12th edition by Martin and Cook, Mack Publishing Company (1961). A bulky, insoluble powder should be mixed beforehand with a small proportion of the base mixture or propylene glycol and then blended with the remainder of the base. These products are usually improved by passing them through an oinment or roller mill. Many substances insoluble in conventional greasy bases will dissolve in the Water-soluble propylene glycol ointment base to give completely homogeneous ointments. It may be desirable at times to add the medicinal as an alcoholic or aqueous solution, and these are readily miscible with the water-soluble bases. Coal tar, ichthammol, balsam Peru and others that require special processing in greasy bases can be readily incorporated in the base of this invention. The medicant can be incorporated into the final base or introduced into the base mixture with one of its components.
Medicants which are insoluble in propylene glycol can be dissolved or suspended in the melted fatty alcohol composition. Heat sensitive medicants (in particular some antibiotics) can be dissolved or suspended in a small amount of glycol solvent or other liquid, and then mixed with the vehicle during or after its preparation.
The amount of medicant to be incorporated into the base will, of course, depend upon the type of medicant and its intended use; the determination of suitable medicant concentrations is a routine matter fully within the conventional skills of the art. In general, therapeutically effective amounts of the medicant are incorporated into the vehicle.
The vehicle of this invention is particularly suitable for use with anti-inflammatory topical steroids represented by Formulas I, II and III.
R is hydrogen, methyl, fiuoro, or chloro and when Z is a single bond, R can be either a or B oriented;
R is hydrogen, chloro, or fluoro;
R is keto or wherein R is hydrogen, hydroxy, chloro, or fluoro;
R is hydrogen, methyl, hydroxy, or conventional hydrolyzable esters thereof;
R is hydrogen, hydroxy, conventional hydrolyzable esters thereof, or when taken together with R ...0 /Re )a .0 R7
wherein R is hydrogen or alkyl of up to eight carbons, and
R is hydrogen, or alkyl or an aryl group of up to eight carbons;
R is hydroxy, conventional hydrolyzable esters thereof, tetrahydropyranyloxy, tetrahydrofuranyloxy, 4'-(lower)- alkoxytetrahydropyran- 4' -yloxy, lower alkoxy, lower cycloalkoxy, lower cycloalkenyloxy, chloro, or fluoro;
R and R are hydrogen, methyl, phenyl, chlorophenyl, fluorophenyl, methylphenyl, or methoxyphenyl (the substituted phenyls preferably being substituted in the para position);
R and R each is hydrogen, chloro, or fluoro;
Z and Z each is a single bond, double bond, or
The terms (lower)alkyl and derivations thereof appearing in the above definitions and elsewhere in the instant specification denote alkyl groups having from one to six carbon atoms, inclusive, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, amyl, hexyl, and the like.
The term conventional hydrolyzable ester as used herein denotes those hydrolyzable ester groups conventionally employed in the steroid art, preferably those derived from hydrocarbon carboxylic acids or phosphoric acids and their salts. The term hydrocarbon carboxylic acid defines both substituted and unsubstituted hydrocarbon carboxylic acids. These acids can be completely saturated or possess varying degrees of unsaturation (including aromatic), can be of straight chain, branched chain, or cyclic structure, and preferably contain from one to 12 carbon atoms. In addition, they can be substituted by functional groups, for example, hydroxy, alkoxy containing up to six carbon atoms, acyloxy containing up to 12 carbon atoms, nitro, amino, halogeno and the like, attached to the hydrocarbon backbone chain. Typical conventional hydrolyzable esters thus included within the scope of the term and the instant invention are acetate, propionate, butyrate, valerate, caproate, enanthrate, caprylate, pelargonate, acrylate, undecenoate, phenoxyacetate, benzoate phenylacetate, diphenylacetate, diethylacetate, trimethylacetate, t-butylacetate, trimethylhexanoate, methylneopentylacetate, cyclohexylaceate, cyclopentylpropionate, adamantoate, glycolate, methoxyacetate, hemisuccinate, hemiadipate, hemi-(Lfi-dimethylglutarate, acetoxyacetate 2-chloro-4-nitrobenzoate, aminoacetate, diethylaminoacetate, piperidinoacetate, ,B-chloropropionate, trichloroacetate, ,B-chlorobutyrate, dihydrogen phosphate, dibenzyl phosphate, benzyl hydrogen phosphate, sodium benzyl phosphate, cyclohexylammonium benzyl phosphate, sodium phenyl phosphate, sodium ethyl phosphate, di-p-nitrobenzyl phosphate, sodium o-methoxyphenyl phosphate, cyclohexylammonium p-cyanobenzyl phosphate, sodium phenacyl phosphate benzyl o-carbomethoxyphenyl phosphate, and the like.
By the term aryl are included aryl, aralkyl, and alkaryl groups, such as phenyl, p-chlorophenyl, p-methoxyphenyl, benzyl, phenethyl, tolyl, ethylphenyl, and the like. The wavy line (E) designates and includes both the alpha and beta configurations.
The above anti-inflammatory steroids have been previously disclosed in United States Patents 3,365,446, 3,067,- 194, 3,364,203 and 3,053,838 for example.
The 4-(lower)alkoxytetrahydropyran-4'-yl are prepared from the corresponding hydroxy compounds by reacting the latter compounds under substantially anhydrous conditions with an excess of 4'-(lower)alkoxy-5',6'- dihydro-ZH-pyran. The reaction is conducted in the presence of a small amount of an acidic catalyst, such as hydrochloric acid, p-toluenesulfonic acid, boron trifluoride etherate, and the like, either alone or together with an inert, organic solvent such as benzene, diethyl ether, or the like, at a temperature ranging from about 0 C. to about C. for about five minutes to about 48 hours, thus giving the corresponding 21-(4'-loweralkoxytetrahydropyran-4-yloxy) ethers as explained more fully in United States Patent application Ser. No. 731,299 filed May 22, 1968.
Prior to the above reaction, protection should be provided for readily etherified hydroxyl groups other than the C-21 hydroxyl groups, eg 16a-hydroxy group. Such a group should be selectively acylated such as by reaction with acetic anhydride in pyridine, the quantity of acetic anhydride being sufficient to acylate both the C-16 and C-2l hydroxyl groups. Hydrolysis of the diacetate in methanol with less than one molar equivalent of sodium carbonate in water yields the l6-acetoxy-2l-hydroxy product which can be separated by conventional chromatography on neutral alumina, for example. After the above etherification, the acetoxy protecting groups can be removed by treatment of the ester in a methanol solution of potassium hydroxide.
The above anti-inflammatory topical medicants are thoroughly mixed with the base in therapeutically effective amounts. The particular concentration of the medi cant in the base will vary depending upon the particular activity of the steroid used considered in conjunction with thet condition and subject to be treated. In general, therapeutically effective amounts of these compounds can be as low as 0.00001 weight percent or lower, for example. For some uses, as high as 5 weight percent steroid or higher may be desired.
The medicant base of this invention has been found to be unexpectedly superior to previously known vehicles for use with known topical corticoids, for example fluocinolone acetonide (6a,9a-ditluoro-l1B,21-dihydroxy-l6a, 17u-isopropylidenedioxypregna-l,4-diene-3,20-dione) and the corresponding 21 acetate (6a,9a-difiuoro-1lB-hydroxy- 16a,l7a-isopropylidenedioxy 21 acetoxypregna-l,4-diene-3,20-dione). In preliminary tests, these medicants have been observed to have several times greater activity in comparison to their activity in previously known vehicls at the same concentration.
This invention is further illustrated by the following specific but non-limiting examples.
EXAMPLE 1 The following ingredients were mixed at 90 C. and cooled to room temperature with good agitation.
Contration, wt. percent Formula A B Ingredients:
Cetyl alcohol T. 35 9. O 12. 60 Stearyl aleohol ti. 8. 00 .7. Behenyl alcohol. ll. 12. 00 13. (35 Propylene glycol 74. 80 70. 50 64. 30
1 Lil-propylene diol.
These compositions were found to have the spreadability, penetrability and solvent powder required for use with medicants such as steroids, anesthetics, antiseptics, antibiotics and the like.
EXAMPLE 2 The compositions of Example 1 were found to have greater plasticity and uniformity when mixed with polyethylene glycol and/or hexanetriol to provide the following formulas.
Formula D Ingredients: Concentration, wt. percent Cetyl alcohol 1.75 Stearyl alcohol 7.00
Behenyl alcohol 12.25 Polyethylene glycol 5.00 1,2,6-hexanetriol 6.00 Propylene glycol 2 68.00
1 molecular weight 6000. Z 1,2-propylcne diol.
EXAMPLE 3 Concentration, wt. percent Formula E 1 Ingredients:
Cetyl alcohol 1. 75 1. 75 Stearyl alcohol 3. 50 7. 00 Behenyl alcohol 12. 25 I 75 Stearic acid 3. 50
Stearamidc 4. 00 Polyethylene glycol 5. 00 5. 00 1,2,G-hexanetrioL 0. 00 6. 00 Propylene glycol 2 68. 00 60. 50
1 Molecular weight 6,000. 3 1,2-propylene diol.
EXAMPLE 4 Following the general procedure of Example 3, a formula based entirely on stearyl alcohol for the saturated monohydric alcohol was found to be suitable. The ingredients of this formula are shown below.
Formula G Concentration Ingredients: wt. percent Stearyl alcohol 30.0 Propylene glycol 70.0
1 LLB-propylene diol.
EXAMPLE 5 Following the general procedure of Example 3, the following satisfactory formulations can be prepared.
Concentration, wt. percent Formula designation II I J Ingredients:
Stearyl alcohol 25 Stearic acid Polyethylene glycol 1 Hexanetriol 2 Sorbitan monostearate. Propylene glycol It Polyethylene glycol 4 1 Molecular weight, 6,000. 2 1,2,6-hexanetriol.
4 Molecular weight, 400.
EXAMPLE 6 In this example, 0.25 gm. of 6a,9a-difiuoro-ll/3-hydroxy-16a,17a-isopropylidenedioxy 21 acetoxypregna- 1,4-diene-3,20-dione, was mixed with 100 gm. of Formula A, Example 1 to form a highly effective anti-inflammatory mixture. The steroid was dissolved in 680 gm. of propylene glycol at 9095 C. The latter then was mixed with a mixture of the other ingredients at 85 C. The mixture was cooled to room temperature with good agitation, mixed with the remainder of the propylene glycol heated to 45 C., allowed to settle and deaerate overnight, gently mixed and filled into containers.
The mixture was tested and found to be mold and bacteria resistant as follows. The test organisms used in the study were Bacteria: ATCC# Pseudomonas aeruginosa 10145 Proteus vulgaris 881 Staphylococcus aureus 6538 Bacillus cereus 11778 Molds:
Aspergullus niger 9642 Penicillium luteum 9644 Candida albicans 10231 Tricophyton mentagrophytes 9533 The test procedure was as follows:
Twenty-four hour broth cultures of the listed bacteria were prepared in Tryptose Phosphate Broth. The molds were grown in Sabouraud Liquid Medium. Just prior to the performance of the assay, all the test organisms were diluted 1:100 with the specific media as diluent. 0.01 ml. of each diluted organism was intimately mixed with a 15 ml. portion of the test material. Test samples inoculated with the mixture of bacteria were incubated at 37 C., and portions inoculated with the mixture of molds were incubated at room temperature. At the end of 48 hours contact and two weeks contact, samples were removed and plated out on appropriate media using the standard serial dilution technique.
The test compounds were found to be highly effective against both bacteria and mold pooled cultures after two days and two weeks exposure.
The procedure, repeated with 6a,9ot-difluoro-115,2l-dihydroxy 16,17a isopropylidcnedioxypregna-1,4-diene- 3,20-dione, yielded the same results.
EXAMPLE 7 The steroids used in Example 6 (0.25 gm.) are mixed with 1000 gm. of each of Formulas B, C, D, E, F, G, H, I, J, K and L by the general procedure described in Example 6, the steroid being dissolved in glycol solvent before being mixed with the other components. The product compositions are mold and bacteria resistant when tested by the procedure described in Example 6.
Each of 0.25, 0.5 and 1.0 gm. quantities of the following anti-inflammatory steroids, when mixed with 1000 gm. of each of the vehicles described in Examples 1-5, inclusive, are effective for topical treatment of inflammation:
9a-fiuoro-1 15, 170:,21-trihydroxy-165-methylpregna- 1,4-diene-3 ,20-dione,
9ot-fluoro-l 15,21 -dihydroxy- 1 65-methyl- 17a-valeroxypregna-l ,4diene-3,20-dione,
17a,21-dihydroxypregn-4-ene-3,11,20-trione, 17u-hydroxy-21-acetoxypregn-4-ene-3 ,1 l ,20-t1'ione, 21-hydroxypregn-4-ene-3 ,20-dione, 21-acetoxypregn-4-ene-3 ,20-dione, 2 l-pivaloxypregn-4-ene-3,20-dione, 9u-fluoro-1 15,17 u,21-trihydroxy- 16 u-methylpregnal,4-diene3,20-dione,
9a-fluoro- 1 15,l7a,21-trihydroxy-16 u-methylpregna- 1,4-diene-3,20-dione-2l-sodium phosphate,
6oz,9ct-difl1l0f0-l 15,2l-dihydroxy-16a,17a-isopropylidenedioxypregna-1,4-diene-3 ,20-dione,
6a,9a-difluoro-1 15-hydroxy-16a,17 OL-iS opropylidenedioxy-2 l-acetoxypregna-l,4-diene-3,20-dione,
6a-methyl-9 ot-fluoro-l 15,17u-dihydroxypregna-1,4- diene-3 ,20-dione,
6cc-flu01'0- 1 15,17a,21-trihydroxypregna-1 ,4-diene- 3,20-dione,
6 a-fluoro-l 15,21-dihydroxy- 1 6 OL-170t-lSOPIOPY1ld6I16- dioxypregn-4-ene-3 ,20-dione,
6u-fluoro-1 15,2 l-dihydroxy-16u,17a-is0propylidenedioxypregna-l ,4-diene-3,20-dione,
115,17u-dihydroxy-2l-acetoxypregn-4-ene-3 ,20-dione, 6a-methyl-1 15, l7a,2l-trihydroxypregna-1,4-diene- 3 ,20-dione,
6a-methyl-115,17ot-dihydroxy-2l-acetoxypregna- 1,4-diene-3 ,20-dione,
6a-fluoro- 115, 17a,21-trihydroxy- 1 6a-methylpregna- 1,4-diene-3,20-dione,
6u-fluoro-l 15,17 oc-dihYdI'OXY-l 6a-methyl-2 l-acetoxypregnal ,4-diene-3,20-dione, I
6 a-fluoro- 1 15,17 u-dihydroxy-16a-methyl-2l-valeroxypregna-l ,4-diene-3,20-dione,
115,17a,21-trihydroxypregna-1,4-diene-3,20-dione, 1 15,17a-dihydroxy-2l-acetoxypregna-1,4-diene- 3 ,20- dione,
17a,2 l-dihydroxypregna-l ,4-diene-3 ,1 1,20-trione, 17a-hydroxy-21-acetoxypregna-1,4-diene-3, 11,20-trione, 9ot-fluoro-1 15,16a,17a,2l-tetrahydroxypregna-1,4- diene-3,20-dione,
9a-fluoro-1 15, 16oz, 17 u-trihydroXy-Z l-acetoxypre gna- 1,4-diene-3 ,20-dione,
9u-fluoro-l 15,2l-dihydroxy-16a,17u-isopropylidenedioxypregnal ,4-diene-3 ,20-dione,
6ot-fi11OI'O-9oz,l 15-dichloro-16a,17a-isopropylidenedioxy-21-hydroxypregna- 1 ,4-diene-3 ,20-dione,
6a,9a-difluoro-l 15,17a,21-trihydroxy-16a-methylpregna-l,4-diene-3 ,20-dione,
6oc-flllOIO-1 15,21-dihydroxy-l6ot-methylpregna-1,4- diene-3 ,20-dione, and
6a,9a-difluoro-1 15-hydroxy-16a,17u-isopropy1idenedioxy-21-chloropregna-l ,4-diene-3 ,20-dione.
The invention claimed is:
1. A substantially anhydrous composition consisting essentially of an effective amount of a topical medicament and a vehicle consisting essentially of (a) from 15 to 45 parts by weight saturated fatty alcohol having from 16 to 24 carbons,
(b) from 45 to parts by weight of glycol solvent,
(c) from 0 to 15 parts by weight of compatible plasticizer,
(d) from 0 to 15 parts by weight of compatible coupling agent, and
(e) from 0 to 20 parts by weight of penetrant, the composition being substantially free from petrolatum, mineral oil, monohydric fatty alcohols and fatty acids which are unsaturated and monohydric alcohols, fatty acids and fatty amides which have less than 16 carbons.
2. The composition of claim 1 wherein the vehicle consists essentially of (a) from 20 to 35 parts by weight saturated fatty alcohol having from 16 to 24 carbons,
(b) from 55 to 80 parts by weight of glycol solvent,
(c) from 2 to 10 parts by weight of compatible plasticizer, and
(d) a concentration of coupling agent suflicient to prevent visible exudation of the glycol solvent from the composition after storage for 48 hours at 45 C.,
(e) and from 0 to 10 parts by weight penetrant.
3. The composition of claim 1 wherein the glycol solvent is propylene glycol, polyethylene glycol having a molecular weight of from to 800, dipropylene glycol or mixtures thereof.
4. The composition of claim 1 wherein the compatible plasticizer is polyethylene glycol having a molecular weight of from above 800 up to 20,000, hexanetriol, sorbitol, glycerol or mixtures thereof.
5. The composition of claim 1 wherein the compatible coupling agent is fatty acid having from 16 to 24 carbons, fatty amide having from 16 to 24 carbons, fatty acid monoester with aliphatic alcohols or mixtures thereof.
6. The composition of claim 1 wherein the medicament is an anti-inflammatory steroid.
7. The composition of claim 6 wherein the steroid is (a) a pregn-4-ene-3,20-dione having at each of positions C-1, 2 and C-6, 7, a single bond, double bond or group having the formula wherein R and R each is hydrogen, chloro or fiuoro; at position C-6, hydrogen, methyl, fluoro or chloro; at position C-9, hydrogen, chloro, or fluoro; at position C-11, keto or wherein R is hydrogen, hydroxy, chloro or fluoro; at position C-16, hydrogen, methyl, hydroxy or conventional hydrolyzable esters thereof, at position C-17rx, hydrogen, hydroxy, conventional hydrolyz- 12 able esters thereof, or when taken together with able esters thereof, or when taken together with C-16a, a group having the formula C16 1, a gr up havi g t e f rmula R ---O\ /Ru C o --0 R1 7 wherein R is hydrogen or alkyl of up to 8 carbons, wherein R is hydrogen or alkyl of up to 8 carbons, and 7 is Y alkyl or W having P 3 and R7 is hydrogen, or alkyl or al-yl having up to 3 carbons; and at position C-21, hydroxy, conventional hydrolyzable esters thereof, tetrahydropyranyloxy,
tetrahydrofuranyloxy, 4' (lower)alkoxytetrahydropyran-4-yloxy, lower alkoxy, lower cycloalkoxy, lower cycloalkenyloxy, chloro or fluoro.
8. The composition of claim 7 wherein the steroid is carbons; and at position C21, hydroxy, conventional hydrolyzable esters thereof, tetrahydropyranyloxy, tetrahydrofuranyloxy, 4'- (lower)alkoxytetrahydropyran-4'-yloxy, lower alkoxy, lower cycloy cycloalkenyloxy chloro or fiuoro; 6a,9a-difluoro-11,8-hydroxy-16a,17a-isoproylidene dioxy- (b) a 2 -substrtuted-pregn-4-en-20-one-[3,2-c]-pyrazole 2l acetoxypregna l,4 diene 3,zo dionc Ora -p -BJ- J- y 9. The composition of claim 7 wherein the steroid is having at the respective 0r positions, 6a,9ot-difluoro-11fl,2l-dihydroxy-16a,l7a isopropylidenedrogen, methyl, p y chlorophenyl, fluorophenyl, dioxypregna-l,4-diene3,20-dione.
methylphenyl, or methoxyphenyl, and having at 20 10. The composition of claim 7 wherein the steroid is 7, a single bond, double bond or group having the 6oc-fluoro-9a,11fi-dichloro-16u,17a isopropylidenedioityformula 2l-hydroxypregna-1,4-diene-3,20-dione.
i d 0 References C to f UNITED STATES PATENTS R12 2,173,337 9/1939 Miescher et al. 424-240 2,600,344 6/1952 Van Meter 424-240 wherein R and R each is hydrogen, chloro or 2,779,707 1/1957 Jacobson et aL 424 240 fluoro; at position hydrogen, methyl fluoro or 2,841,527 7/1958 Freedman et al. 424-240 chloro; at position hydrogen, chloro, or fiuoro; 2,856,329 10/1958 Taylor et al. 424-240 at position C-11, keto 0r 3,071,511 1/1963 Sasaki et al. 424-243 3,210,248 10/1965 Feldmann et al. 424-239 H 3,352,753 11/1967 Lerner 424-241 3,472,931 10/1969 Stoughton 424-240X wherein R is hydrogen, hyzdroxy, chloro or fluoro; SHEP ROSE, Primary Examiner at position C-16, hydrogen, methyl, hydroxy or conventional hydrolyzable esters thereof, at position U.S. Cl. X.R. C-17oz, hydrogen, hydroxy, conventional hydrolyz- 40 424-241, 358
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 930 Dated y 1971 Inventor(s) Martin Katz and Herbert M. Neiman It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
F- Column 5, lines 30-43, that portion of the formula should be \Nk A Column 11, line 37, "hyzdroxy" should read hydroxy Signed and sealed this 18th day of July 1 972.
( SEAL Attest:
EDWARD M.FLETCHER,JR. ROBERT GOTTSCHALK Attesting Officer Commissioner of Patents
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3863633 *||May 24, 1972||Feb 4, 1975||Pharmacia Ab||Composition containing a substance showing a topical effect on the eye, and a method of preparing the same|
|US3867528 *||Oct 11, 1973||Feb 18, 1975||American Cyanamid Co||Steroidal topical cream base|
|US3883661 *||Oct 16, 1973||May 13, 1975||Syntex Inc||Acne treatment|
|US3888995 *||Mar 3, 1971||Jun 10, 1975||Syntex Corp||Fatty alcohol-propylene glycol vehicle|
|US3924004 *||Nov 24, 1971||Dec 2, 1975||Syntex Corp||Fatty alcohol-propylene carbonate-glycol solvent cream vehicle|
|US3987198 *||Jan 17, 1975||Oct 19, 1976||Syntex (U.S.A.) Inc.||Method for lowering the free fatty acid content in sebum using certain fatty acid amides|
|US4017615 *||Dec 11, 1975||Apr 12, 1977||Syntex Corporation||Propylene carbonate ointment vehicle|
|US4082881 *||Dec 23, 1976||Apr 4, 1978||E. R. Squibb & Sons, Inc.||Topical and other type pharmaceutical formulations containing isosorbide carrier|
|US4496554 *||Oct 15, 1981||Jan 29, 1985||E. R. Squibb & Sons, Inc.||Oleaginous emollient vehicle for steroid formulations|
|US4626539 *||Jun 10, 1985||Dec 2, 1986||E. I. Dupont De Nemours And Company||Trandermal delivery of opioids|
|US4775529 *||May 21, 1987||Oct 4, 1988||Schering Corporation||Steroid lotion|
|US4954487 *||Feb 15, 1989||Sep 4, 1990||The Procter & Gamble Company||Penetrating topical pharmaceutical compositions|
|US4963555 *||Mar 1, 1989||Oct 16, 1990||Burroughs Wellcome Co.||Formulations of heterocyclic compounds|
|US5132101 *||Sep 6, 1990||Jul 21, 1992||Cytopharm, Inc.||Acetylene-cumulene porphycene compounds for photodynamic therapy|
|US5173302 *||Sep 28, 1990||Dec 22, 1992||Medtronic, Inc.||Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs|
|US5179120 *||Jun 28, 1991||Jan 12, 1993||Cytopharm, Inc.||Porphycene compounds for photodynamic therapy|
|US5244671 *||Jan 29, 1991||Sep 14, 1993||Cytopharm, Inc.||Derivatives of porphycene for photodynamic therapy of cancer|
|US5610175 *||Apr 6, 1995||Mar 11, 1997||Cytopharm, Inc.||9-Substituted porphycenes|
|US5948822 *||Nov 25, 1997||Sep 7, 1999||Lidak Pharmaceuticals||Treatment of hyperproliferative skin disorders with C18 to C26 alphatic alcohols|
|US5952392 *||Aug 22, 1997||Sep 14, 1999||Avanir Pharmaceuticals||Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition|
|US6313179||Dec 11, 1998||Nov 6, 2001||Avanir Pharmaceuticals||Treatment of hyperproliferative skin disorders with C18 to C20 aliphatic alcohols|
|US6440980||Mar 10, 1999||Aug 27, 2002||Avanir Pharmaceuticals||Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs|
|US6723750||Mar 15, 2002||Apr 20, 2004||Allergan, Inc.||Photodynamic therapy for pre-melanomas|
|US7091190||Jul 16, 2002||Aug 15, 2006||Avanir Pharmaceuticals||Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs|
|US7771733||Jan 24, 2007||Aug 10, 2010||Medicis Pharmaceutical Corporation||Compositions and methods for enhancing corticosteroid delivery|
|US7794738||Jan 24, 2007||Sep 14, 2010||Medicis Pharmaceutical Corporation||Compositions and methods for enhancing corticosteroid delivery|
|US7964751||Feb 25, 2008||Jun 21, 2011||Yeda Research And Development Co. Ltd.||Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses|
|US8232264||Jan 29, 2009||Jul 31, 2012||Medicis Pharmaceutical Corporation||Compositions and methods for enhancing corticosteroid delivery|
|US8987263||Oct 9, 2003||Mar 24, 2015||Meir Shinitzky||Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents|
|US20030073651 *||Jul 16, 2002||Apr 17, 2003||Marcelletti John F.||Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs|
|US20040033982 *||Oct 15, 2002||Feb 19, 2004||Katz David H||Viral inhibition by n-docosanol|
|US20040198709 *||Apr 16, 2004||Oct 7, 2004||Gans Eugene H.||Compositions and methods for enhancing corticosteroid delivery|
|US20040247604 *||Apr 11, 2002||Dec 9, 2004||Cohen Irun R.||Anti-inflamatory fatty alcohols and fatty acid esters useful as antigen carriers|
|US20060173053 *||Oct 9, 2003||Aug 3, 2006||Meir Shinitzky||Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents|
|US20060183797 *||Apr 11, 2002||Aug 17, 2006||Cohen Irun R||Fatty alcohols and fatty acid esters useful for treatment of inflammation|
|US20070142343 *||Jan 24, 2007||Jun 21, 2007||Gans Eugene H||Compositions and methods for enhancing corticosteroid delivery|
|US20070142344 *||Jan 24, 2007||Jun 21, 2007||Gans Eugene H||Compositions and methods for enhancing corticosteroid delivery|
|US20080221115 *||Feb 25, 2008||Sep 11, 2008||Liat Hayardeny-Nisimov||Use of long-chain alcohol derivatives for the treatment of alopecia areata|
|US20080221209 *||Feb 25, 2008||Sep 11, 2008||Yaacov Herzig||Enantiomers of amino-phenyl-acetic acid octadec-9-(z) enyl ester, their salts and their uses|
|US20090176750 *||Jan 29, 2009||Jul 9, 2009||Gans Eugene H||Compositions and methods for enhancing corticosteroid delivery|
|US20100210609 *||Jan 29, 2009||Aug 19, 2010||Eugene Gans||Compositions and methods for enhancing corticosteroid delivery|
|US20100210614 *||Jan 24, 2007||Aug 19, 2010||Eugene Gans||Compositions and methods for enhancing corticosteroid delivery|
|US20100210615 *||Jan 24, 2007||Aug 19, 2010||Eugene Gans||Compositions and methods for enhancing corticosteroid delivery|
|DE2515599A1 *||Apr 10, 1975||Oct 30, 1975||Squibb & Sons Inc||Arzneimittel zur lokalen anwendung und verfahren zu ihrer herstellung|
|DE2661037C2 *||Jun 3, 1976||Apr 6, 1989||Syntex (U.S.A.) Inc., Palo Alto, Calif., Us||Title not available|
|EP0215622A2||Sep 8, 1986||Mar 25, 1987||Syntex (U.S.A.) Inc.||Naphthalene anti-psoriatic agents and process for making them|
|EP1385500A1 *||Apr 11, 2002||Feb 4, 2004||YEDA RESEARCH AND DEVELOPMENT Co. LTD.||Fatty alcohols and fatty acid esters useful for treatment of inflammation|
|EP1385500A4 *||Apr 11, 2002||Dec 29, 2004||Yeda Res & Dev||Fatty alcohols and fatty acid esters useful for treatment of inflammation|
|WO2007025244A2||Aug 25, 2006||Mar 1, 2007||Houle Philip R||Treatment systems for delivery of sensitizer solutions|
|U.S. Classification||514/172, 514/174, 514/176|
|International Classification||A61K47/00, A61K9/00|
|Sep 8, 1986||AS37||To correct the name of the assignee|
Free format text: SYNTEX PHARMACEUTICAL INTERNATIONAL LIMITED * SYNTEX CORPORATION, A CORP OF PANAMA : 19860828
|Sep 8, 1986||AS||Assignment|
Owner name: SYNTEX PHARMACEUTICAL INTERNATIONAL LIMITED
Free format text: TO CORRECT THE NAME OF THE ASSIGNEE IN AN ASSIGNMENT RECORDED AUGUST 11, 1982 AT REEL 4068, FRAMES 237-250 ASSIGNOR DOES HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST.;ASSIGNOR:SYNTEX CORPORATION, A CORP OF PANAMA;REEL/FRAME:004605/0712
Effective date: 19860828
|Jun 7, 1985||AS||Assignment|
Owner name: SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED A CO
Free format text: RE-RECORD TO EXCLUDE PATENT 3,592,930 INADVERTENTLY RECITED IN DOCUMENT PREVIOUSLY RECORDED AUGUST 11, 1982, REEL 4068 FRAME 0237 ASSIGNORS HEREBY ASSIGN AS OF APRIL 1, 1981 THE ENTIRE INTEREST IN SAID OATENT TO SAID ASSIGNEE.;ASSIGNORS:SYNTEX CORPORATION A CORP OF PANAMA;SYNTEX (U.S.A.) INC. A DE CORP;REEL/FRAME:004419/0303
Effective date: 19850606
Free format text: RE-RECORD TO EXCLUDE PATENT 3,592,930 INADVERTENTLY RECITED IN DOCUMENT PREVIOUSLY RECORDED AUGUST 11, 1982, REEL 4068 FRAME 0237 ASSIGNORS HEREBY ASSIGN AS OF APRIL 1, 1981 THE ENTIRE INTEREST IN SAID OATENT TO SAID ASSIGNEE;ASSIGNORS:SYNTEX CORPORATION A CORP OF PANAMA;SYNTEX (U.S.A.) INC. A DE CORP;REEL/FRAME:4419/303
Owner name: SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED A COR
Free format text: RE-RECORD TO EXCLUDE PATENT 3,592,930 INADVERTENTLY RECITED IN DOCUMENT PREVIOUSLY RECORDED AUGUST 11, 1982, REEL 4068 FRAME 0237 ASSIGNORS HEREBY ASSIGN AS OF APRIL 1, 1981 THE ENTIRE INTEREST IN SAID OATENT TO SAID ASSIGNEE;ASSIGNORS:SYNTEX CORPORATION A CORP OF PANAMA;SYNTEX (U.S.A.) INC. A DE CORP;REEL/FRAME:004419/0303
|Jun 7, 1985||AS99||Other assignments|
Free format text: SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED A CORP OF BERMUDA * SYNTEX CORPORATION A CORP OF PANAMA : 19850606; SYNTEX (U.S.A.) INC. A DE CORP : 19850606 OTHER CASES: NONE; RE-RECORD TO EXCLUDE PATENT 3,592,930 INADVERTENTLY RECITED
|Aug 11, 1982||AS02||Assignment of assignor's interest|
Owner name: SYNTEX (U.S.A.) INC.
Effective date: 19820719
Owner name: SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED, A CO
|Aug 11, 1982||AS||Assignment|
Owner name: SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED, A CO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST. EFFECTIVE APRIL 1, 1981.;ASSIGNOR:SYNTEX (U.S.A.) INC.;REEL/FRAME:004068/0237
Effective date: 19820719